A clinician’s guide to HLA matching in allogeneic hematopoietic stem cell transplant

Mangum, David Spencer; Caywood, Emi

doi:10.1016/j.humimm.2022.03.002

Cited by 13 publications

(8 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, evaluation for signs of immune tolerance breakdown, through the assessment of cellular subpopulations imbalance or its product (such as cytokines or chemokines) ( 128 ) and its correlation with known clinical signs of placental dysfunction (i.e., angiogenic markers or fetal & maternal Doppler), could also be explored. Moreover, HLA screening and matching could also be considered as a suitable tool attempting to decrease the reported immune tolerance disbalance ( 129 ).…”

Section: Discussionmentioning

confidence: 99%

Pregnancies through oocyte donation. A mini review of pathways involved in placental dysfunction

Caradeux,

Fernández,

Ávila

et al. 2024

Front. Med.

View full text Add to dashboard Cite

Pregnancies resulting from assisted reproductive techniques (ART) are increasingly prevalent worldwide. While most pregnancies conceived through in-vitro fertilization (IVF) progress without complications, mounting evidence suggests that these pregnancies are at a heightened risk of adverse perinatal outcomes. Specifically, IVF pregnancies involving oocyte donation have garnered attention due to numerous reports indicating an elevated risk profile for pregnancy-related complications within this subgroup of patients. The precise mechanisms contributing to this increased risk of complications remain incompletely understood. Nonetheless, it is likely that they are mediated by an abnormal immune response at the fetal–maternal interface. Additionally, these outcomes may be influenced by baseline patient characteristics, such as the etiology of infertility, absence of corpus luteum, and variations in endometrial preparation protocols, among other factors. This review aims to succinctly summarize the most widely accepted mechanisms that potentially contribute to the onset of placental dysfunction in pregnancies conceived through oocyte donation.

show abstract

Section: Discussionmentioning

confidence: 99%

Pregnancies through oocyte donation. A mini review of pathways involved in placental dysfunction

Caradeux,

Fernández,

Ávila

et al. 2024

Front. Med.

View full text Add to dashboard Cite

show abstract

“…Donor–recipient HLA allele matching is an essential component of allogeneic hematopoietic stem cell transplant (HSCT) and high‐resolution HLA genotyping is routinely used for donor and recipient selection 1,2 . Here, we describe a novel HLA‐DRB1 allele, now officially named as HLA‐DRB1*11:283, that has been identified in a Chinese leukemia patient and his daughter.…”

Section: Figurementioning

confidence: 99%

Characterization of the novel HLA‐DRB1*11:283 allele

Dong

Liu

Chen

et al. 2023

HLA

View full text Add to dashboard Cite

Methionine). The full HLA genotype o the individual bearing these alleles shown in Table 1.The names of these HLA alleles have been officially assigned by the World Health Organization (WHO) Nomenclature Committee for Factors of the HLA System in January and February 2023. This follows the agreed policy that, subject to the conditions stated in the most recent Nomenclature Report, 3 names will be assigned to new sequences as they are identified. Lists of such new names will be published in the following WHO Nomenclature Report.

show abstract

“…The HLA genes are the most polymorphic in the human genome, which have evolved to allow the immune system to sense foreign pathogens and provide wide-ranging protection (18,19). The classical HLA genes are comprised of the Class I and Class II genes that present peptide antigen to T cells.…”

Section: Hla Antibodies In Hsctmentioning

confidence: 99%

“…Expression of Class II can be induced on other cell types, particularly in the setting of inflammation. Historically, HLA matching for HSCT patients and donors was performed for HLA-A, -B, -C, and -DR (8/8 loci matching), owing to limited typing methods that precluded typing at HLA-DQ and -DP (19). Currently, with the widespread and growing use of next-generation sequencing to perform genotyping, matching is clinically assessed at HLA-A, -B, -C, -DR, -DQ (10/10 loci matching) although data is available for donors and recipients at all HLA loci, including HLA-DP, -DRB345, -DQA1, and -DPA1.…”

Section: Hla Antibodies In Hsctmentioning

confidence: 99%

Donor specific HLA antibody in hematopoietic stem cell transplantation: Implications for donor selection

Krummey

Gareau

2022

Front. Immunol.

View full text Add to dashboard Cite

Advances in hematopoietic stem cell transplant (HSCT) have led to changes in the approach to donor selection. Many of these new approaches result in greater HLA loci mismatching, either through the selection of haploidentical donors or permissive HLA mismatches. Although these approaches increase the potential of transplant for many patients by expanding the number of acceptable donor HLA genotypes, they add the potential barrier of donor-specific HLA antibodies (DSA). DSA presents a unique challenge in HSCT, as it can limit engraftment and lead to graft failure. However, transient reduction of HLA antibodies through desensitization treatments can limit the risk of graft failure and facilitate engraftment. Thus, the consideration of DSA in donor selection and the management of DSA prior to transplant are playing an increasingly important role in HSCT. In this review, we will discuss studies addressing the role of HLA antibodies in HSCT, the reported impact of desensitization on DSA levels, and the implications for selecting donors for patients with DSA. We found that there is a clear consensus that moderate strength DSA should be avoided, while desensitization strategies are reported to be effective in most cases at reducing DSA to amenable levels. There is limited information regarding the impact of specific characteristics of DSA, such as HLA loci or overall level of sensitization, which could further aid in donor selection for sensitized HSCT candidates.

show abstract

A clinician’s guide to HLA matching in allogeneic hematopoietic stem cell transplant

Cited by 13 publications

References 60 publications

Pregnancies through oocyte donation. A mini review of pathways involved in placental dysfunction

Pregnancies through oocyte donation. A mini review of pathways involved in placental dysfunction

Characterization of the novel HLA‐DRB1*11:283 allele

Donor specific HLA antibody in hematopoietic stem cell transplantation: Implications for donor selection

Contact Info

Product

Resources

About